Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676089 | 0.93 | GPR119 (0.50) | GPR119PRMT5WDR77NAMPTTP53 | |
| SCHEMBL3940077 | 0.93 | USP30 (0.49) | GPR119PRMT5WDR77NAMPTOPRM1 | |
| SCHEMBL4118999 | 0.92 | GPR119 (0.49) | GPR119PRMT5WDR77NAMPTTP53 | |
| SCHEMBL2675407 | 0.86 | USP30 (0.48) | GPR119PRMT5WDR77NAMPTMAPK1 | |
| SCHEMBL4114242 | 0.85 | USP30 (0.47) | GPR119PRMT5WDR77NAMPTTP53 | |
| SCHEMBL5255129 | 0.84 | TP53 (0.53) | GPR119TP53KDM4EPTPN2PTPN1 | |
| SCHEMBL5254230 | 0.84 | TP53 (0.53) | GPR119TP53NPC1RAB9A | |
| SCHEMBL7149147 | 0.84 | L3MBTL1 (0.56) | OPRM1OPRD1OPRK1OPRL1KDM4E | |
| SCHEMBL15009205 | 0.83 | HTR1A (0.50) | — | |
| SCHEMBL4993502 | 0.83 | ESR2 (0.48) | GPR119TP53STSNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4455145-A2 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | Astraea Therapeutics, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | ASTRAEA THERAPEUTICS, LLC | 2024-02-22 | — | — | US | disclosed |
| US-RE49825-E1 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
| US-20210053937-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2021-02-25 | — | — | US | disclosed |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC | 2020-11-10 | — | — | US | disclosed |
| EP-3710426-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | Bioimics AB (SE) | 2020-09-23 | — | — | EP | disclosed |
| CN-111566085-A | Anti-infective heterocyclic compounds and uses thereof | 百欧伊米克思有限公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| CN-1186322-C | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2005-01-26 | — | — | CN | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| CN-1441779-A | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | GPR119 116/4885PRMT5 3188/4885WDR77 3556/4885 |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | GPR119 116/4885PRMT5 3188/4885WDR77 3556/4885 |
| US-20210053937-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRM1 | GPR119 116/4885PRMT5 3188/4885WDR77 3556/4885 |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | GPR119 186/4885PRMT5 668/4885WDR77 1983/4885 |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | GPR119 4399/4885PRMT5 3212/4885WDR77 2751/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | GPR119 186/4885PRMT5 668/4885WDR77 1983/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | GPR119 159/4885PRMT5 758/4885WDR77 1810/4885 |
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | OPRL1, OPRK1, OPRM1 | GPR119 116/4885PRMT5 3188/4885WDR77 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.